

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500034. Telangana, India.

CONTACT**MEDIA RELATIONS**

USHA IYER

USHAIYER@DRREDDYS.COM

Second Dr. Anji Reddy Memorial Lecture delivered by Nobel Laureate Prof. Jack W. Szostak

- *The Dr. Anji Reddy Memorial Lecture is an annual lecture series instituted in 2023 to honour founder-Chairman Dr. K. Anji Reddy's passion for deep science and innovation*
- *The 2024 Dr. Anji Reddy Memorial Lecture was delivered by Nobel Laureate (Physiology or Medicine, 2009), Professor Jack W. Szostak on 'RNA and the Origin of Life'*
- *Padma Shri awardee and the first Indian recipient of the Harold Rifkin Award, Dr V. Mohan, led the tributes to Dr. Anji Reddy*
- *The event brought together eminent personalities representing science, industry, academia and Government*
- *The inaugural Dr. Anji Reddy Memorial Lecture in 2023 was delivered by Nobel Laureate Prof. Ada E. Yonath, Nobel Laureate (Chemistry, 2009), along with a keynote address by Dr. K. VijayRaghavan, Former Principal Scientific Advisor, Government of India*

Hyderabad, India; March 15, 2024 – Dr. Reddy's Laboratories Limited ('Dr. Reddy's') today hosted the second edition of the Dr. Anji Reddy Memorial Lecture, an annual lecture series instituted to honour the memory of the scientist, entrepreneur and philanthropist, Dr. K. Anji Reddy, on the eleventh anniversary of his passing.

With 'Science, Society and Sustainability' at its core, the lecture series was initiated by Dr. Reddy's Laboratories Limited and Dr. Reddy's Institute of Life Sciences in 2023 to represent these key pillars of his life and legacy.

This year, the Dr. Anji Reddy Memorial Lecture was delivered by **Nobel Laureate (Physiology or Medicine, 2009), Professor Jack W. Szostak** on 'RNA and the Origin of Life'. Prof. Szostak began by expressing his admiration for Dr. Anji Reddy's passion for science and his ability to blend it with business for societal impact. He also acknowledged the importance of the newly-established Center for Rare Disease Models (CRDM) at the Dr. Reddy's Institute of Life Sciences (DRILS) in Hyderabad, which he inaugurated yesterday. The Center aims to bring academia, clinics and industry together to develop research models to understand rare diseases better and explore potential approaches for therapies. In his lecture entitled 'RNA and the Origin of Life,' Professor Szostak highlighted the RNA molecule's dual role as a villain, seen in the SARS-CoV-2 virus, and a savior, as seen in the mRNA vaccine. He further discussed his lab's current research on the transition from chemical to biological evolution on the planet Earth in its earliest days. This includes studying each step of the hypothesised evolutionary process,

such as identifying the nature of monomers and the acquisition of self-replication capabilities, leading to the emergence of "primitive life".

Padma Shri awardee in the field of Diabetology and the first Indian recipient of the Dr. Harold Rifkin Distinguished International Service in the Cause of Diabetes Award from the American Diabetes Association, **Dr. V. Mohan, Chairman, Dr. Mohan's Diabetes Specialities Centre**, shared memories of his work and friendship with Dr. Anji Reddy. Through anecdotes, Dr. Mohan described Dr. Anji Reddy as a loyal friend and a dreamer who thought big, his passion for science, and his unwavering focus on innovation, patients and society.

In his opening remarks, **G.V. Prasad, Co-Chairman & Managing Director, Dr. Reddy's**, welcomed the distinguished speakers and guests at the event. He spoke about Dr. Anji Reddy's pioneering spirit which translated into the company's efforts to be first to bring drugs to market for patients. Describing Dr. Anji Reddy as a leader who put planet and patients above profits, he pledged that as the company completes 40 years, it would re-dedicate itself to advancing medicine for the betterment of society.

Delivering the closing remarks, **Satish Reddy, Chairman, Dr. Reddy's**, underscored the importance of science and innovation in Dr. Anji Reddy's life and work, and pointed to several new recent developments in pharmaceutical innovation as encouraging examples. Thanking the speakers and guests for their participation and their reminiscences of Dr. Anji Reddy's warmth, friendship, laughter and passion for science, he promised that the company would chase Dr. Anji Reddy's unfinished agenda of new drug discovery and taking it to market.

A live recording of the event is accessible here: https://www.youtube.com/watch?v=74LnC3L3y_k.

About Dr. K Anji Reddy: Recognised as a visionary scientist, entrepreneur and philanthropist, Dr. K. Anji Reddy (10th August 1941 – 15th March 2013) was the founder of Dr. Reddy's Laboratories Limited. He was born in 1941 in Tadepalli village in Andhra Pradesh, India. Having completed his B.Sc. Tech degree at the University Department of Chemical Technology, Mumbai, Dr. K. Anji Reddy earned a doctorate in Chemical Engineering from the National Chemical Laboratory, Pune. Dr. Reddy joined the state-owned Indian Drugs and Pharmaceuticals Ltd (IDPL), an experience that stoked his entrepreneurial ambitions. In 1984, he established Dr. Reddy's Laboratories Limited. Under the stewardship of Dr. K. Anji Reddy, the company grew from strength to strength. From 1990s onwards, the company broke new frontiers to expand globally. Dr. K. Anji Reddy's commitment towards deep science and innovation led Dr. Reddy's to be pioneer in the Indian pharmaceutical industry. In 1993, Dr. Reddy's became the first Indian pharma company to embark on new drug discovery with the set-up of Dr. Reddy's Research Foundation. In 2001, Dr. Reddy's become the first Asian pharmaceutical company outside Japan to be listed on the New York Stock Exchange. As the fastest growing pharma company in India, Dr. Reddy's crossed the USD 1 billion revenue mark in 2006 and USD 2 billion in 2012. Several firsts – in marketing exclusivity in the U.S., biosimilars, product launched in key markets – followed.

Dr. K. Anji Reddy had always envisioned bringing molecules to India at a price the common man could afford. He was equally determined to give back to society and create sustainable livelihoods. He identified the lack of opportunity for livelihoods as a major cause of indigence, and encouraged initiatives that would address this need. In 1996, Dr. K. Anji Reddy set up Dr. Reddy's Foundation. Continuing Dr. K. Anji Reddy's vision, since then the Foundation has engaged in several impactful initiatives in health, education, livelihood and environmental sustainability.

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad, India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of 'Good Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Our major markets include – USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.